论文部分内容阅读
在一项新的研究中,来自瑞典、法国、比利时和瑞士的一个研究团队发现一种方法逆转对一种用于治疗肺结核的抗生素药物产生的耐药性。在他们发表在Science期刊上的论文中,该团队描述了他们如何筛选激活用于活化ethionaide的不同通路的化合物。Ethionaide是一种被用来治疗肺结核的前体分子,在体内经过代谢后产生一种真正有疗效的药物。开发治疗细菌性感染的抗生素已明显地让这个世界变得更加健康。不幸的是,随着时间的推移,细菌不断地进化出挫败这些抗生素的能力,
In a new study, a team of researchers from Sweden, France, Belgium and Switzerland found a way to reverse the resistance to an antibiotic drug used to treat tuberculosis. In their paper published in Science journals, the team described how they screened compounds that activate different pathways for activating ethionaide. Ethionaide is a precursor molecule that is used to treat tuberculosis and is metabolized in the body to produce a truly potent drug. The development of antibiotics to treat bacterial infections has clearly made the world healthier. Unfortunately, over time, bacteria have evolved to thwart these antibiotics,